EX-12.1

Exhibit 12.1

Regeneron Pharmaceuticals, Inc.
Computation of Ratio of Earnings to Combined Fixed Charges
(Dollars in thousands)


															Nine months
	Years ended December 31,														ended September 30,
	2003			2004		2005			2006			2007			2008
Earnings:
Income (loss) from continuing operations before income (loss) from equity investee	$	(107,395	)	$	41,565	$	(95,456	)	$	(103,150	)	$	(105,600	)	$	(48,113	)
Fixed charges		14,108			14,060		13,687			13,643			13,708			9,751
Amortization of capitalized interest		33			78		78			73			23			15
Interest capitalized		(276	)		—		—			—			—			—


Adjusted earnings	$	(93,530	)	$	55,703	$	(81,691	)	$	(89,434	)	$	(91,869	)	$	(38,347	)


Fixed charges:
Interest expense	$	11,932		$	12,175	$	12,046		$	12,043		$	12,043		$	7,457
Interest capitalized		276			—		—			—			—			—
Assumed interest component of rental charges		1,900			1,885		1,641			1,600			1,665			2,294


Total fixed charges	$	14,108		$	14,060	$	13,687		$	13,643		$	13,708		$	9,751


Ratio of earnings to fixed charges		(A	)		3.96		(A	)		(A	)		(A	)		(A	)


(A)		Due to the registrant’s losses for the years ended December 31, 2003, 2005, 2006, and 2007, and for the nine months ended September 30, 2008, the ratio coverage was less than 1:1. To achieve a coverage ratio of 1:1, the registrant must generate additional earnings of the amounts shown in the table below.